# The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas

> **NCT02701257** · NA · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 20 (actual)

## Conditions studied

- Diabetes Mellitus Type 1

## Interventions

- **DEVICE:** iPhone bionic pancreas
- **DEVICE:** iLet bionic pancreas
- **DRUG:** Xeris Xerisol glucagon
- **DRUG:** Lilly glucagon
- **DEVICE:** iLet infusion set
- **DEVICE:** Contact Detach infusion set

## Key facts

- **NCT ID:** NCT02701257
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03
- **Primary completion:** 2018-05
- **Final completion:** 2018-05
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** The study was terminated prior to completing the planned cohorts and analysis because of problems with the infusion set resulting in inadequate insulin delivery
- **Last updated:** 2019-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02701257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02701257, "The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02701257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*